Research programme: VAP-1 SSAO enzyme inhibitors - Biotie TherapiesAlternative Names: BTT-2027; VAP-1 SMI; VAP-1 SSAO enzyme inhibitor
Latest Information Update: 06 Dec 2013
At a glance
- Originator Biotie Therapies Corp.
- Class Small molecules
- Mechanism of Action AOC3 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Inflammation